Search company, investor...

NanoPass Technologies

nanopass.com

Founded Year

2000

Stage

Corporate Minority | Alive

About NanoPass Technologies

NanoPass Technologies develops and commercializes painless intradermal (skin) delivery solutions for vaccines and large molecules. NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.

Headquarters Location

3 Golda Meir Street Park ha'mada

Nes Ziona, 7403648,

Israel

+972-(0)8-9462905

NanoPass Technologies's Product Videos

DSC3007.png

Compete with NanoPass Technologies?

Ensure that your company and products are accurately represented on our platform.

NanoPass Technologies's Products & Differentiators

    MicronJet600

    Injection device for vaccines

NanoPass Technologies Patents

NanoPass Technologies has filed 13 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Medical equipment
  • Membrane biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/1/2020

4/5/2022

Medical equipment, Drug delivery devices, Microtechnology, Membrane biology, Routes of administration

Grant

Application Date

4/1/2020

Grant Date

4/5/2022

Title

Related Topics

Medical equipment, Drug delivery devices, Microtechnology, Membrane biology, Routes of administration

Status

Grant

Latest NanoPass Technologies News

Microneedle Drug Delivery Systems Global Market Research Report 2022 - ResearchAndMarkets.com

Jun 3, 2022

June 03, 2022 10:30 AM Eastern Daylight Time Major players in the microneedle drug delivery systems market are 3M, Zosano Pharma, Becton-Dickinson Technologies, Nanopass Technologies, Corium, Valeritas, Microdermics, TheraJect Inc, LTS Lohmann Therapie-Systeme AG, and BioSerenTach (BT). The global microneedle drug delivery systems market is expected to grow from $3.26 billion in 2021 to $3.60 billion in 2022 at a compound annual growth rate (CAGR) of 10.3%. The market is expected to grow to $6.64 billion in 2026 at a compound annual growth rate (CAGR) of 16.6%. The microneedles drug delivery systems market consists of sales of microneedle drug delivery systems by entities (organizations, sole traders, and partnerships) which allow the users to adapt to the safer alternative process of drug delivery. Microneedles drug delivery system is a device with hundreds of microneedles on a patch that delivers a sufficient amount of drug in treatment. Microneedles drug delivery systems are also known as microneedle patches. The main types of technologies in microneedle drug delivery systems are solid microneedle technology, hollow microneedle technology, dissolved microneedle technology, and others. Peptides are dried on the tips of a microneedles array in the solid microneedle's method, which uses a coating of powerful chemicals. The solid microneedles are 250 micrometers to 700 micrometers in length and come in patch form that can be stored at room temperature. The microneedle drug delivery systems are used for drug delivery, vaccine delivery, others and employed in diagnostic laboratories, life sciences, research laboratories, hospitals, ambulatory surgical centers, and others. Increasing research and demand for the vaccination process are predicted to drive the microneedle drug delivery systems market growth. Researchers view microneedle as an alternative way to inject vaccines where the receiver of the vaccine is expected to not feel any sensation of pain. Microneedle patches vaccine was developed initially for flu and measles, however, the technology is now being used increasingly for delivery of COVID-19 vaccine as well. For instance, in 2020, The University of Connecticut, Vaxess, and Verndari are using microneedles to deliver viral proteins into the skin, where they induce an immune response. According to a Bloomberg report, more than 3.98 billion doses of vaccine have been administered across 180 countries until July 2021. Increased demand from government and health research and development bodies for microneedle drug delivery technology propels the market for microneedle drug delivery systems going forward. Biodegradable microneedles drug delivery patches are increasingly used in local therapeutic gene delivery and treatment of chronic diseases. The use of biodegradable microneedles patches helps in easy and fast delivery of genes through targeting the skin as a site for local delivery. Gene delivery and treatment with these patches are easily accessible and contain fluid and lymph vessels that help the genetic material to act effectively. Biodegradable microneedles patches offer several advantages in gene delivery such as improved efficacy, fast delivery, customized delivery, and others. Key Topics Covered:

NanoPass Technologies Frequently Asked Questions (FAQ)

  • When was NanoPass Technologies founded?

    NanoPass Technologies was founded in 2000.

  • Where is NanoPass Technologies's headquarters?

    NanoPass Technologies's headquarters is located at 3 Golda Meir Street, Nes Ziona.

  • What is NanoPass Technologies's latest funding round?

    NanoPass Technologies's latest funding round is Corporate Minority.

  • Who are the investors of NanoPass Technologies?

    Investors of NanoPass Technologies include Medimop Medical Projects, Ofer Hi-Tech, D-Partners, WFD Ventures, Israel Healthcare Ventures and 3 more.

  • Who are NanoPass Technologies's competitors?

    Competitors of NanoPass Technologies include Impel NeuroPharma, Corium International, Critical Pharmaceuticals, Ekos, Transpharma and 13 more.

  • What products does NanoPass Technologies offer?

    NanoPass Technologies's products include MicronJet600 and 1 more.

  • Who are NanoPass Technologies's customers?

    Customers of NanoPass Technologies include Fillmed.

Compare NanoPass Technologies to Competitors

A
Aegis Biosciences

Aegis Biosciences is a developer of biomaterial drug delivery and wound healing technologies.

E
Erydel

EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

C
Corium International

Corium International applies advanced transdermal delivery systems and related technologies to address unmet medical needs. The company has developed two highly differentiated transdermal technologies: MicroCor, a biodegradable microstructure patch technology for active delivery of proteins, peptides and vaccines large molecules that require active transport through the skin; Corplex, an adhesive system and patch technology for delivery of small molecules that may otherwise be difficult to formulate and deliver.

O
Optotrack

Optotrack, Inc. is a high-tech company leading in the research and development of optical, imaging, chemical, as well as biological sensors and microsystems. The company is dedicated to commercializing its intellectual properties based on microfabrication and nanotechnology to seize rapidly growing market opportunities in the industries of healthcare, communication, and homeland security. Optotrack, Inc. offers a broad range of technology and business solutions from design through production to marketing and sales. The company combine decades of industry experience and R&D expertise in thin-film science, polymer engineering, solid-state sensing, digital imaging, optoelectronics, RF circuitry, medical diagnostics, microfluidics, and drug delivery to provide enabling technologies to the company's partners, customers, and community. The firm aims to deliver products and services of exceptional quality to cast the future, to improve the life quality for everyone.

C
Cambridge Eyenovations

Cambridge Eyenovations is developing drug-eluting contact lenses that can dispense medicine automatically for glaucoma patients so that people don't need to put in eyedrops at all, and can go a month without changing contact lenses.

W
Westfield Life Sciences Fund

Launched in July of 2000, the Westfield Life Sciences Fund invests in healthcare companies across the capitalization spectrum including medical devices, drugs, drug delivery, biotechnology, and healthcare services. Portfolio manager Will Muggia employs a fundamental, bottom up research driven process that focuses on preservation of capital and long-term outperformance. Westfield's industry network developed by Mr. Muggia and his analytical team is critical to new idea generation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.